IL-1βmAb has no direct effect on human cartilage explants
| . | Control . | IL-1βmAb (10 ng/mL) . | P . |
|---|---|---|---|
| PG synthesis rate | 4.33 (2.94-8.97) | 4.73 (3.42-8.74) | .55 |
| GAG release | 1.38 (0.97-2.27) | 1.21 (0.97-2.29) | .87 |
| GAG content | 24.73 (20.56-28.08) | 25.53 (22.49-27.69) | .50 |
| . | Control . | IL-1βmAb (10 ng/mL) . | P . |
|---|---|---|---|
| PG synthesis rate | 4.33 (2.94-8.97) | 4.73 (3.42-8.74) | .55 |
| GAG release | 1.38 (0.97-2.27) | 1.21 (0.97-2.29) | .87 |
| GAG content | 24.73 (20.56-28.08) | 25.53 (22.49-27.69) | .50 |
Proteoglycan turnover parameters in the absence of blood, expressed as median with interquartile range (n = 7; independent cartilage donors).
PG, proteoglycan.